Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.


  1. Home


  2. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.


  3. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.

Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD. Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States. Clin Ther. 2013 Apr;35(4):414-24. doi: 10.1016/j.clinthera.2013.02.

Upcoming Events

Full Calendar


News Categories